SecBot SecBot
PRESS-RELEASE ·Filed Oct 26, 2026

IMRX

Immuneering Corporation
NEUTRAL
Impact 3/10
Processed44m ago Wirepress-3387994
Press release · FDA

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3387994
12 reports for IMRX
Performance horizon
60% Hit rate @ T+1 3 of 5 directional calls Went positive at some point 4 of 5 best @ T+60▲ +20.33%Jun 1, 2026
Filters
Rows
Reports for IMRX — sortable, filterable
TypeNow
Oct 26, 2026
today
Press Release
NEUTRAL ★ 3/10
—awaiting T+1——
Oct 2, 2026
23d ago
Press Release
NEUTRAL ★ 3/10
$4.07 $4.04▼ −0.74%▼ −1.41%$3.73 (−8.35%)
Sep 28, 2026
28d ago
Press Release
BULLISH ★ 6/10
$4.16 $4.13▼ −0.72%▼ −0.54%$3.73 (−10.34%)
Aug 26, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$5.21 $4.99▼ −4.22%▼ −4.00%$3.73 (−28.41%)
Aug 5, 2026
11w ago
8-K
NEUTRAL ★ 5/10
$4.39 $4.46▲ +1.59%▲ +1.75%$3.73 (−15.03%)
Aug 5, 2026
11w ago
Press Release
NEUTRAL ★ 5/10
$4.39 $4.46▲ +1.59%▲ +1.75%$3.73 (−15.03%)
Jun 11, 2026
19w ago
Institutional Cluster
NEUTRAL ★ 3/10
$4.12 $4.19▲ +1.70%▲ +1.16%$3.73 (−9.47%)
Jun 1, 2026
20w ago
8-K
BULLISH ★ 7/10
$4.28 $4.55▲ +6.31%▲ +7.00%$3.73 (−12.85%)
May 15, 2026
23w ago
Press Release
BULLISH ★ 7/10
$5.16 $4.87▼ −5.62%▼ −5.56%$3.73 (−27.71%)
Apr 21, 2026
26w ago
Press Release
BULLISH ★ 7/10
$5.89 $6.13▲ +4.07%▲ +4.47%$3.73 (−36.67%)
Showing 10 of 12

US Market Status

Market Closed — Opens in 1h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh IMRX Intelligence

Analysis is for subscribers only.

Immuneering presented a trial-in-progress poster at ESMO 2026 for its pivotal Phase 3 trial (MAPKeeper 301) evaluating atebimetinib plus modified chemotherapy in first-line metastatic pancreatic cancer. The trial builds on Phase 2a data showing median overall survival of 17.3 months, which…

Subscribe for Full Access